LBI-HTA - Publications - Search - Horizon Scanning in Oncology 35th Prioritisation – 2nd quarter 2018

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 35th Prioritisation – 2nd quarter 2018. HSO: 35th Prioritisation.

[img]PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
511Kb
Abstract

For the 35th prioritisation (March 2018), eight drugs were filtered out of 404 identified and were sent to prioritisation. Of these, six drugs were ranked as 'highly relevant' by the expert panel, one as 'relevant' and one as 'not relevant'. For 'highly relevant' drugs, further information including, for example, abstracts of phase III studies and licensing status is contained in this document.

Item Type:DSD: Horizon Scanning in Oncology
Subjects:WB Practice of medicine > WB 300-962 Therapeutics
QZ Pathology > QZ 200-380 Neoplasms.Cysts
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Language:English
Series Name:HSO: 35th Prioritisation
Deposited on:06 Apr 2018 12:31
Last Modified:06 Apr 2018 12:35

Repository Staff Only: item control page